MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue
The 2025 National Medical Insurance (MediCare) Negotiation kicked off at 8:30 AM, marking the start of...
Policy / Regulatory
National Health Commission Unveils Fourth Drug List for Generic Development
The National Health Commission (NHC) today released its fourth catalogue of medicines earmarked for generic...
SSY Group Limited Projected to Win 12 Products in China’s Eleventh VBP Round
China‑based SSY Group Limited (HKG: 2005) announced today that it has been pre‑selected as the...
NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5
The National Medical Products Administration (NMPA) today issued the “Measures for the Administration of Drug...
Novartis Asciminib Enters China’s SPARK Program for Pediatric Chronic Myeloid Leukemia
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced today...
NMPA Expands Reference Listed Drugs List to 98 Items for Chemical Generic Drugs
China’s National Medical Products Administration (NMPA) today released its 98th Reference Listed Drugs (RLD) list...
VBP 11th Finalizes 389 Participants, 3.7 Billion Doses Set for Centralized Procurement
The Office of the National Drug Joint Procurement (ONDJP) published the conclusive enterprise roster for...
Pfizer CEO Bourla Highlights Benefits of China Biotech Collaborations at NY Gala
Albert Bourla, CEO of Pfizer Inc. (NYSE: PFE), highlighted the benefits of collaborations between multinational...
National Joint Procurement Office Announces 11th Round VBP, AstraZeneca Dapagliflozin Leads Demand
On October 11, 2025, the National Joint Procurement Office (NJPO) released the full company list for...
State Council Introduces 2026 Regulations Governing Clinical Research of Biomedical New Technologies in China
The Chinese State Council has issued the Regulations on the Administration of Clinical Research and...
National Drug Alliance Moves VBP 11th‑Round Information Disclosure Conference to 27 Oct 2025 in Shanghai
The National Drug Alliance Procurement Office announced a schedule change for the 11th round of...
NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs
The National Medical Products Administration (NMPA) has issued a new regulatory framework, titled “Announcement on...
Trump’s New Pharmaceutical Tariffs Will Be Limited to 15% for EU and Japan, White House Says
A White House spokesperson clarified that President Donald Trump’s proposed tariffs on imported pharmaceuticals will not...
NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign
The National Healthcare Security Administration (NHSA) announced a nationwide 100‑Day Action aimed at eradicating illegal...
China Unveils National Long‑Term Care Insurance Service Catalog in Pilot Phase
The National Healthcare Security Administration (NHSA) released the National Long‑Term Care Insurance Service Catalog (Trial),...
Fosun Pharma’s Alovatinib Enters China’s Pediatric Anti‑Tumor SPARK Pilot
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that...
Trump Administration Expands Section 232 Tariffs on Robotics, Industrial Machinery and Medical Devices
President Donald J. Trump’s administration has opened new investigations under Section 232 of the Trade Expansion Act, targeting...
China Drug Procurement: Centralized Rules Shape 11th Round Of VBP
The Joint Procurement Office of the National Healthcare Security Administration (NHSA) published the definitive rules...
National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation
The National Healthcare Security Administration (NHSA) today issued a notice outlining a multi‑city pilot program...